Posterior reversible encephalopathy syndrome in neuroblastoma patients receiving anti-GD2 3F8 monoclonal antibody Academic Article uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal
  • Brain Neoplasms
  • Immunoglobulin G
  • Neuroblastoma
  • Posterior Leukoencephalopathy Syndrome

abstract

  • Patients who receive anti-GD2 MoAb immunotherapy should be closely monitored for, and undergo urgent treatment or evaluation of, symptoms that may herald PRES (eg, hypertension or headaches). Prior brain irradiation may be a predisposing factor for PRES with this immunotherapy.

publication date

  • August 2013

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4326066

Digital Object Identifier (DOI)

  • 10.1002/cncr.28137

PubMed ID

  • 23633099

Additional Document Info

start page

  • 2789

end page

  • 95

volume

  • 119

number

  • 15